Implications on PSMA Targeted Therapy
Dr. Haffizulla: So, what’s new about PSMA-targeted therapy and how likely is it to impact practice?
Dr. Sartor: Well, you know, this is a very rapidly changing area. You know, if we had had a discussion of this 2 years ago, there probably would’ve been very little to say. But right now, based on experiences predominately in Germany and Australia, there is clear evidence of activity for PSMA-targeted therapy, particularly with something like Lutetium-177, and it’s also with other rated pharmaceuticals as well, a little bit of activity with Actinium-225 and Bismuth-213.
So, right now the idea of using a PSMA-targeting mechanism to bring in isotope into the tumor and then radiate that tumor very specifically is an area very, very, very active investigation. Now what’s interesting and exciting is there’s going to be a planned phase III. A little company called Endocyte has actually acquired the rights to PSMA-617, and there is planning actively right now for a phase III trial, and I think this could potentially be a game changer. In fact, as of all the changes in prostate cancer therapy I think this actually may be the most exciting one, the one that I have my eyes closest on at this time.
Dr. Haffizulla: Excellent. Well, we are waiting with bated breath to hear more on it.
Dr. Sartor: We’re going to get more data, and when we get more data it’ll be intriguing to have those discussions.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: